Drug Trial Radar · NCT05741242
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
136
Planned (sponsor's estimate)
Start
Nov 30, 2022
Primary completion
Jan 2027
Study completion Jan 2029
Sponsor
- Lead sponsor
- Jaime Leandro Foundation for Therapeutic Cancer VaccinesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Conditions
- Cancer
- Solid Tumor
Interventions
Personalized Synthetic Long Peptide VaccineBiological
Personalized Synthetic Long Peptide Vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).Time frame: Until progression or death, assessed up to 12 months post first vaccine administration.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Precision NextGen Oncology & Research Center
Beverly Hills, California
Quest Clinical Research
San Francisco, California
Asthra Health
Santa Monica, California
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
St. Louis Cancer Care
Bridgeton, Missouri
Anna Gattani MD PC
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.